The Hematologic Malignancies and Cellular Therapies (HMCT) program is a multidisciplinary clinical, basic and translational research effort whose overall goal is to improve outcomes for patients with hematological malignancies. The broad, long-term goal of the HMCT Program is to build on and extend the current knowledge in the field of hematopoietic stem cell transplantation, immunotherapy and hematological malignancies, and to develop novel strategies for improving therapeutic results in patients with hematological malignancies through a collaborative and integrated approach involving the basic, translational and clinical investigators of the Program. The scientific goals of the Program are: 1) To understand hematopoietic stem cell development and control of differentiation and to optimize the use of allogeneic and autologous transplantation of hematopoietic stem cells and compare various alternative sources of hematopoietic stem cells for allogeneic transplantation; 2) To understand the basic biology of graft versus tumor (GvT) and to explore new ways to induce GvT effects and improve immune reconstitution without significant graft versus host disease (GvHD) following allogeneic stem cell transplantation; 3) To develop genomic signatures for hematological malignancies and evaluate the importance of different signaling mechanisms in leukemogenesis or lymphomagenesis; 4) To understand the biology of T cells and their roles in cancer immunology and immunotherapy; 5) To develop adoptive immunotherapy with natural killer (NK) cells and chimeric antigen receptor (CAR) T cells, and active immunotherapy with dendritic cell (DC)-based vaccine trials in combination with Toll-like receptor (TLR) agonists and/or immune checkpoint blockade strategies for hematological malignancies; 6) To study the biology of B cells and its implication s in hematologic malignancies, vaccine design and chronic GvHD; 7) To identify new cellular and stromal targets for therapy with antibodies or small molecules, leading to evaluation of various labeling techniques, such as using radiolabels or diphtheria toxins, of small molecules and antibodies with subsequent clinical evaluation of safety and efficacy; 8) To design and execute Phase I and Phase II clinical trials in hematological malignancies based on novel laboratory discoveries within the Program. The Program includes 43 primary and 9 secondary members from 9 basic and clinical departments within Duke University. Total direct funding for program members is $54M, of which $36M (67%) is from peer- reviewed sources. From 2009-2013, program members published 707 papers in peer- reviewed journals cited in PubMed. Of these publications, 86 (12.2%) are the result of intra-programmatic collaborations, 101(14.3%) are from inter-programmatic collaborations, and 29 (4.1%) are from both intra- and inter-programmatic collaborations.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Galaz-Montoya, Monica; Wright, Sara J; Rodriguez, Gustavo J et al. (2017) ?2-Adrenergic receptor activation mobilizes intracellular calcium via a non-canonical cAMP-independent signaling pathway. J Biol Chem 292:9967-9974
Lanier, Megan L; Park, Hyeri; Mukherjee, Paramita et al. (2017) Formal Synthesis of (+)-Laurencin by Gold(I)-Catalyzed Intramolecular Dehydrative Alkoxylation. Chemistry 23:7180-7184
Shi, Qiong; Liu, Hongliang; Han, Peng et al. (2017) Genetic Variants in WNT2B and BTRC Predict Melanoma Survival. J Invest Dermatol 137:1749-1756
Woyach, Jennifer A; Ruppert, Amy S; Guinn, Daphne et al. (2017) BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol 35:1437-1443
Wang, Yanru; Freedman, Jennifer A; Liu, Hongliang et al. (2017) Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. Int J Cancer 141:731-743
Fayanju, Oluwadamilola M; Hall, Carolyn S; Bauldry, Jessica Bowman et al. (2017) Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. Am J Surg 214:666-671
Leu, David; Spasojevic, Ivan; Nguyen, Huy et al. (2017) CNS bioavailability and radiation protection of normal hippocampal neurogenesis by a lipophilic Mn porphyrin-based superoxide dismutase mimic, MnTnBuOE-2-PyP5. Redox Biol 12:864-871
Sauer, Scott J; Tarpley, Michael; Shah, Imran et al. (2017) Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. Carcinogenesis 38:252-260
Pan, Yongchu; Liu, Hongliang; Wang, Yanru et al. (2017) Associations between genetic variants in mRNA splicing-related genes and risk of lung cancer: a pathway-based analysis from published GWASs. Sci Rep 7:44634
Yin, Jieyun; Liu, Hongliang; Liu, Zhensheng et al. (2017) Pathway-analysis of published genome-wide association studies of lung cancer: A potential role for the CYP4F3 locus. Mol Carcinog 56:1663-1672

Showing the most recent 10 out of 480 publications